×
Revance Therapeutics Common Stock Net 2012-2024 | RVNC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Revance Therapeutics common stock net from 2012 to 2024. Common stock net can be defined as the value of common equity ownership.
View More
Revance Therapeutics Common Stock Net 2012-2024 | RVNC
Prices
Financials
Revenue & Profit
Assets & Liabilities
Margins
Price Ratios
Other Ratios
Other Metrics
Total Assets
Cash on Hand
Long Term Debt
Total Liabilities
Share Holder Equity
Revance Therapeutics common stock net from 2012 to 2024. Common stock net can be defined as the value of common equity ownership.
Related Stocks
Company Name
Market
Cap
Amgen (AMGN)
$171.5B
Vertex Pharmaceuticals (VRTX)
$121.6B
Gilead Sciences (GILD)
$111.4B
Bristol Myers Squibb (BMY)
$110.2B
Regeneron Pharmaceuticals (REGN)
$93B
CSL (CSLLY)
$90B
GSK (GSK)
$76.4B
Argenex SE (ARGX)
$35.6B
Alnylam Pharmaceuticals (ALNY)
$35.3B
BioNTech SE (BNTX)
$26.5B
Biogen (BIIB)
$25.3B
Illumina (ILMN)
$23.9B
Moderna (MRNA)
$21B
BeiGene (BGNE)
$19.9B
Genmab (GMAB)
$14.9B
Incyte (INCY)
$14.7B
Exact Sciences (EXAS)
$12.9B
BioMarin Pharmaceutical (BMRN)
$12.7B
Vaxcyte (PCVX)
$12B
Bio-Techne Corp (TECH)
$11.9B
Sarepta Therapeutics (SRPT)
$11.8B
Insmed (INSM)
$11.7B
QIAGEN (QGEN)
$9.8B
Exelixis (EXEL)
$9.7B
Bio-Rad Laboratories (BIO.B)
$9.3B
Revolution Medicines (RVMD)
$9.2B
Intra-Cellular Therapies (ITCI)
$9.2B
Roivant Sciences (ROIV)
$8.6B
Viking Therapeutics (VKTX)
$8.1B
Legend Biotech (LEGN)
$8.1B